Successful Management of De Novo Acute Hepatitis B Virus Infection With Entecavir in a Living-Donor Liver Transplant Patient

Akbulut S., Harputluoglu M., Yilmaz S.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, vol.16, no.5, pp.635-637, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 5
  • Publication Date: 2018
  • Doi Number: 10.6002/ect.2018.0072
  • Journal Name: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.635-637
  • Keywords: Acute liver failure, Entecavir, Fulminant disease, Tenofovir
  • Inonu University Affiliated: Yes

Abstract

The risk of de novo hepatitis B virus infection is lower after liver transplant using hepatitis B core antibody-negative donors into negative recipients versus hepatitis B core antibody-positive donors but can occur. Here, we present a 34-year-old male patient with acute de novo hepatitis B virus that developed 7 months after successful liver transplant. The case we report here is the first in the literature with regard to both switch from tenofovir to entecavir treatment and the presentation of de novo acute hepatitis B virus after liver transplant. The switch in treatment protocol resulted in significant improvements in serologic and biochemical levels, and the patient was discharged from the hospital on day 35 after admittance.